Fetal-Cell Revival for Parkinson's Disease
the Psychiatry Advisor take:
For the first time in 10 years, a team of neurosurgeons this month will transplant cells from aborted fetuses into the brain of a person suffering from Parkinson's disease. The moratorium on replacement-therapy trials began in 2003 since trials involving the therapy were inconcklusive up to that point and the results were difficult to interpret.
The group, known as the Parkinson’s Disease Global Force, includes scientists from the European, US and Japanese teams about to embark on the trials.
More than 100 patients worldwide received the therapy as part of clinical trials before the moratorium. “But centers used different procedures and protocols — it was impossible to work out why some patients did very well and others didn’t benefit at all,” says neurologist Roger Barker at the University of Cambridge, UK, a member of working group.
The stem cell transplants will break a decade-long international moratorium on the controversial therapy.
Fetal-cell revival for Parkinson's
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- FDA Approves Schizophrenia Medication With Digital Ingestion Sensor
- Increased Depression Severity Following Childhood Exposure to Adversity, Risk
- Suboptimal Neuromotor Development Related to Genetic Risk for Schizophrenia
- No Association Between Comorbid Anxiety Disorders, Suicide Attempts
- Cannabidiol Concentration, Labeling Varies Widely in Products Sold Online
- Maintenance rTMS for Treatment-Resistant Depression
- Eye Movement Desensitization and Reprocessing Reduces PTSD Symptoms
- Micronutrients Improve Some Symptoms of ADHD
- Long-Acting Injectable Antipsychotics Delay Schizophrenia Relapse
- Transcranial Stimulation Reduces Auditory Hallucinations in Schizophrenia
- Borderline Personality Disorder: Not Just an Adult Condition
- Prior Mental Disorders Linked to Subsequent Onset of Chronic Back or Neck Pain
- Posttreatment Brain Effects of Psilocybin in Patients With Treatment-Resistant Depression
- Brexanolone Trials Show Positive Results in Reducing Symptoms of Postpartum Depression
- ADHD Medication Exposure Associated With Increased Neonatal Mortality